References
- De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005;49:2314–21
- Katlama C, Esposito R, Gatell JM, et al. for the POWER 1 study group. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007;21: 395–402
- Haubrich R, Berger D, Chiliade P, et al. for the POWER 2 Study Group. Week 24 efficacy and safety of TMC114/ ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8
- Lazzarin A, Queiroz-Telles F, Frank I, et al. TMC114/r provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. Presented at the 16th International AIDS Conference; August 13–18, 2006; Toronto, Canada [abstract TUAB0104]
- Wilkin T, Haubrich R, Steinhart CR, et al. TMC114/r superior to standard of care in 3-class-experienced patients: 24-wk primary analysis of the POWER 2 study (C202). Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2005; Washington, DC [abstract 2860]
- Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169–78
- Cohen C, Falcon R, Rinehart A, et al. Factors influencing darunavir/ritonavir efficacy in treatment-experienced HIV patients: POWER 1, 2, and 3 pooled 48-week analysis. Presented at the American Society for Microbiology; October 12–15, 2006; Toronto, Canada [abstract 688]
- Molina JM, Cohen C, Katlama C, et al. TMC114/r in treatment-experienced HIV patients in POWER 3: 24-week efficacy and safety analysis. Presented at the 16th International AIDS Conference; August 13–18, 2006; Toronto, Canada [abstract TUPE0060]
- Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet 2007;370:49–58